BIOMAT Database Logo BIOMAT Database Logo

Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia. 2005

Yavuz Beyazit, and Salih Aksu, and Murat Kekilli, and Ibrahim C Haznedaroglu, and Sadettin Kilickap, and Hakan Goker

UI MeSH Term Description Entries
D008206 Lymphatic Diseases Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS. Lymphatism,Status Lymphaticus,Disease, Lymphatic,Diseases, Lymphatic,Lymphatic Disease
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D010996 Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself. Effusion, Pleural,Effusions, Pleural,Pleural Effusions
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D001772 Blood Cell Count The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES. Blood Cell Number,Blood Count, Complete,Blood Cell Counts,Blood Cell Numbers,Blood Counts, Complete,Complete Blood Count,Complete Blood Counts,Count, Blood Cell,Count, Complete Blood,Counts, Blood Cell,Counts, Complete Blood,Number, Blood Cell,Numbers, Blood Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068877 Imatinib Mesylate A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide,CGP 57148,CGP-57148,CGP57148B,Gleevec,Glivec,Imatinib,Imatinib Methanesulfonate,ST 1571,ST1571,STI 571,STI-571,STI571,CGP57148,Mesylate, Imatinib,Methanesulfonate, Imatinib
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Yavuz Beyazit, and Salih Aksu, and Murat Kekilli, and Ibrahim C Haznedaroglu, and Sadettin Kilickap, and Hakan Goker
Imatinib mesylate in chronic myeloid leukemia.
September 2007, Current stem cell research & therapy,
Yavuz Beyazit, and Salih Aksu, and Murat Kekilli, and Ibrahim C Haznedaroglu, and Sadettin Kilickap, and Hakan Goker
Treatment of chronic myeloid leukemia with imatinib mesylate.
June 2006, International journal of clinical oncology,
Yavuz Beyazit, and Salih Aksu, and Murat Kekilli, and Ibrahim C Haznedaroglu, and Sadettin Kilickap, and Hakan Goker
Imatinib mesylate for the treatment of chronic myeloid leukemia.
June 2008, Expert review of anticancer therapy,
Yavuz Beyazit, and Salih Aksu, and Murat Kekilli, and Ibrahim C Haznedaroglu, and Sadettin Kilickap, and Hakan Goker
[Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
January 2004, Vnitrni lekarstvi,
Yavuz Beyazit, and Salih Aksu, and Murat Kekilli, and Ibrahim C Haznedaroglu, and Sadettin Kilickap, and Hakan Goker
[Chronic myeloid leukemia and imatinib mesylate therapy].
January 2004, Vnitrni lekarstvi,
Yavuz Beyazit, and Salih Aksu, and Murat Kekilli, and Ibrahim C Haznedaroglu, and Sadettin Kilickap, and Hakan Goker
Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
July 2005, Leukemia & lymphoma,
Yavuz Beyazit, and Salih Aksu, and Murat Kekilli, and Ibrahim C Haznedaroglu, and Sadettin Kilickap, and Hakan Goker
Spotlight on imatinib mesylate in chronic myeloid leukemia.
January 2004, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Yavuz Beyazit, and Salih Aksu, and Murat Kekilli, and Ibrahim C Haznedaroglu, and Sadettin Kilickap, and Hakan Goker
Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance.
June 2003, Journal of pediatric hematology/oncology,
Yavuz Beyazit, and Salih Aksu, and Murat Kekilli, and Ibrahim C Haznedaroglu, and Sadettin Kilickap, and Hakan Goker
Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases.
February 2005, Experimental hematology,
Yavuz Beyazit, and Salih Aksu, and Murat Kekilli, and Ibrahim C Haznedaroglu, and Sadettin Kilickap, and Hakan Goker
Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience.
December 2006, The Medical journal of Malaysia,
Copied contents to your clipboard!